Werewolf Therapeutics to Present Phase 1/1b Data on WTX-124 at 2024 ASCO Meeting

Werewolf Therapeutics, Inc., a biopharmaceutical company dedicated to developing conditionally activated therapies designed to boost the body’s immune response to cancer, has announced that it will present new clinical data from its ongoing Phase 1/1b trial of WTX-124. This data will be shared at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4 in Chicago, Illinois. The announcement was made on May 23, 2024, via Globe Newswire.

Key Findings and Highlights

The clinical data to be presented involves WTX-124, a conditionally activated Interleukin-2 (IL-2) INDUKINE™ molecule, tested as both a monotherapy and in combination with pembrolizumab. Preliminary findings suggest that WTX-124 is well-tolerated and shows significant clinical activity in patients with locally advanced or metastatic solid tumors who have previously undergone checkpoint inhibitor therapy. The data is based on results from the dose-escalation arms of the Phase 1/1b trial and highlights information as of January 28, 2024, with additional data to be presented based on a cut-off date of May 1, 2024.

Comments from the Leadership

Daniel J. Hicklin, Ph.D., President and CEO of Werewolf Therapeutics, expressed satisfaction with the promising results published in the abstract. He emphasized that these findings not only reinforce the initial data on WTX-124 monotherapy but also demonstrate a well-tolerated profile when combined with pembrolizumab. Hicklin underscored the potential of WTX-124 to meet the significant unmet medical needs among patients with difficult-to-treat solid tumors who have progressed after checkpoint therapy.

Upcoming Event Details

The poster presentation at ASCO will offer further insights into the trial results. The specifics of the presentation are as follows:

- Title: A phase 1/1b study of the IL-2 prodrug WTX-124 in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy: Initial results of the combination dose escalation with pembrolizumab
- Session Date: Saturday, June 1, 2024
- Session Time: 9:00 AM-12:00 PM CDT
- Board Number: 102

The poster will also be available on Werewolf Therapeutics' official website after its presentation at ASCO.

About Werewolf Therapeutics

Werewolf Therapeutics specializes in developing novel therapeutics aimed at stimulating the body’s immune system to treat cancer. Utilizing their proprietary PREDATOR™ platform, they design molecules that activate selectively within the tumor microenvironment while remaining inactive in peripheral tissues. Their leading clinical-stage candidates, WTX-124 and WTX-330, target solid tumors and are designed to be used both as standalone treatments and in combination with immune checkpoint inhibitors. The company aims to advance the development of these candidates across multiple tumor types.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!